To test this hypothesis, we retrospectively analyzed a cohort of 270 JAK2 V617F-positive patients from the Johns Hopkins Center for the Chronic Myeloproliferative Disorders. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.